Small Molecule Drug Candidate Offers Hope for Rare Kidney Stone Disease with No Current Treatment

Small molecule drug candidate offers hope for rare kidney stone disease with no current treatment

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of primary hyperoxaluria type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults. …

Small Molecule Drug Candidate Completely Restores Survival in Lethal Mouse

A groundbreaking discovery from the Buck Institute for Research on Aging may soon rewrite the medical landscape for patients suffering from Primary Hyperoxaluria Type 2 (PH2), an aggressive and devastating genetic disorder known for causing progressive kidney failure in infants and young adults. A small orally administered molecule, N-propargylglycine (N-PPG), has been shown in a […]